SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: jmt who wrote (2549)7/4/1998 11:16:00 PM
From: chirodoc  Respond to of 5402
 
<<<< And if the product does get FDA approval it is currently undervalued.

..as you know it has already been approved for limited use in heart and eye surgery.

.the fact that the fda has already seen and evaluated this molecule will increase their chances.

.also the fact that there has been extensive HUMAN testing is a big plus.

.and i agree with your model of valuation in this sector

curtis


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News